Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udo Holtick

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Molecular Carcinogenesis|May 2, 2024
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltrationAlice N Weaver, Wade T Iams, Jong Chul Park, et al.
American Journal of Hematology|March 31, 2026
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter AnalysisMaximilian Al-Bazaz, Winfried Alsdorf, Lisa Leypoldt, et al.
Nature Medicine|February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibodyTill Braun, Michael Rade, Maximilian Merz, et al.
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Blood Advances|January 9, 2026
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 TrialHyatt Balke-Want, Philipp Gödel, Christoph Schmid, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 12, 2025
Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor-1 Receptor (CSF1R)-Related DisorderHemmo A F Yska, Marianne Golse, Shanice Beerepoot, et al.
Blood Advances|March 25, 2026
Real-world experience with Tabelecleucel within and beyond the approval labelKiavasch Mohammad Nejad Farid, Florian Kocher, Tobias Arnold, et al.
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Blood Advances|January 6, 2023
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from GermanyPeter Bader, Claudia Rossig, Martin Hutter, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Molecular Carcinogenesis|May 2, 2024
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltrationAlice N Weaver, Wade T Iams, Jong Chul Park, et al.
American Journal of Hematology|March 31, 2026
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter AnalysisMaximilian Al-Bazaz, Winfried Alsdorf, Lisa Leypoldt, et al.
Nature Medicine|February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibodyTill Braun, Michael Rade, Maximilian Merz, et al.
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Blood Advances|January 9, 2026
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 TrialHyatt Balke-Want, Philipp Gödel, Christoph Schmid, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 12, 2025
Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor-1 Receptor (CSF1R)-Related DisorderHemmo A F Yska, Marianne Golse, Shanice Beerepoot, et al.
Blood Advances|March 25, 2026
Real-world experience with Tabelecleucel within and beyond the approval labelKiavasch Mohammad Nejad Farid, Florian Kocher, Tobias Arnold, et al.
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Blood Advances|January 6, 2023
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from GermanyPeter Bader, Claudia Rossig, Martin Hutter, et al.
Pageof 10